New data strengthens Teva’s schizophrenia portfolio, including phase 3 SOLARIS trial survey demonstrating patient and healthcare professional satisfaction

Published on

A patient has just received an injection in their arm

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.c, announced the presentation of a patient and healthcare professional (HCP) attitudes and experiences survey study, complementing the successful Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) evaluating TEV-'749.

More than 92% of patients, 87% of nurses and 72% of physicians were either satisfied or very satisfied when asked about TEV-'749, overall, including initiation regimen, monthly dosing schedule and dosing options. The data were presented at the 2025 Congress of the Schizophrenia International Research Society (SIRS) taking place from March 29 to April 2, 2025, in Chicago, IL.

Schizophrenia is an incredibly complex condition with profound impacts on mental health and daily life. That’s why understanding the treatment perspectives of patients and healthcare providers is integral to Teva’s research, and these survey results underscore the personal approach we’ve taken with the development of TEV-'749. This early clinical feedback on TEV-'749 is encouraging across some of the most important schizophrenia treatment factors – dosing schedule, initiation regimen, subcutaneous administration, post-injection monitoring requirements and general satisfaction.

said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva.

With nearly 30 years of clinical and real-world use, olanzapine is one of the most commonly prescribed second-generation oral antipsychotics for the treatment of schizophrenia globally, with a well-established efficacy and safety profile. Teva’s Phase 3 SOLARIS trial program is evaluating the potential of TEV-'749 and its innovative drug delivery technology as a long-acting injectable (LAI) subcutaneous formulation of olanzapine that may also help address the risk of Post-Injection Delirium/Sedation Syndrome (PDSS).

Olanzapine is foundational to the treatment of schizophrenia; however, I have seen first-hand the adherence challenges faced by patients and caregivers with daily oral options. The potential of TEV-'749 as a long-acting formulation of olanzapine that also may not carry a risk for PDSS and the accompanying risk evaluation & mitigation strategy (REMs) and post-injection observation period could be instrumental in helping to treat more people with schizophrenia.

said Andrew J. Cutler, MD, Clinical Associate Professor of Psychiatry, SUNY Upstate Medical University and Chief Medical Officer, Neuroscience Education Institute.

The prospective, cross-sectional, observational and online survey study recruited patient (n=70) and HCP participants (nurses: n=24; physicians: n=11) taking part in the SOLARIS trial who had two or more experiences with TEV-'749. The survey collected information on participants’ demographics and clinical characteristics as well as their attitudes on and experiences with LAI treatment attributes, delivery of care, and treatment satisfaction.

Additional survey findings include:

  • Injection-type preference: Patient preference for subcutaneous (SC) versus intramuscular (IM) injection (78.6% vs. 21.4%, respectively), with 67.3% of patients indicating the needle size as the main reason for their preference. For HCPs, SC versus IM preference was balanced for physicians (54.6% vs. 45.5%, respectively) and nurses (both 50.0%).
  • Post-injection monitoring requirements: Despite reporting low levels of social, emotional, financial or time impact, nearly all patients noted it would be helpful to have an LAI without a post-injection monitoring period (90.0%) or caregiver accompaniment requirement (92.9%). The majority of physicians (>90%) and nurses (>66%) responded that the post-injection monitoring period may present potential treatment barriers and clinical challenges that could impact patients’ use of LAIs. Currently available olanzapine LAI has a three-hour post-injection monitoring requirement.
  • Initiation regimen: When starting an LAI, most participants preferred an initiation regimen requiring only one injection versus more complex regimens requiring concomitant oral medications or multiple injections (patients: 72.9% vs. 27.1%; physicians: 90.9% vs. 9.1%; nurses: 79.2% vs. 20.8%).
  • Dosing schedule: A majority of participants valued a monthly dosing schedule “a lot” (patients: 61.4%; physicians: 72.7%; nurses: 66.7%).
  • TEV-'749 satisfaction: Almost all participants had favorable responses (satisfied or very satisfied) regarding the initiation regimen, dosing schedule and trial medication overall (patients: >92%; physicians: >72%; nurses: >87%), and responded favorably regarding continuing TV-44749 (patients: 82.9%; physicians: 63.6%; nurses: 70.8%). Patients who had prior experience with LAIs were more likely to indicate they were “very satisfied” with trial medication overall (61.9% vs 53.1%). HCPs with more (≥10) TV-44749 experiences were more likely to rate it favorably (88.9% vs 76.5%) and be willing to continue treatment with TV-44749 (83.3% vs 52.9%).

For more information including the full set of data, read the original press release.

For more news from the world of long-acting therapeutics, sign up to the CELT's LONGEVITY mailing list here for regular updates.